Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical trials in dementia with Lewy bodies: the evolving concept of co-pathologies, patient selection and biomarkers.

Current opinion in neurology - 1 Aug 2023

Gibson Lucy L, Abdelnour Carla, Chong Joyce, Ballard Clive, Aarsland Dag

Abstract excerpt

PURPOSE OF REVIEW: Currently, no disease modifying therapies (DMTs) have been approved for use in dementia with Lewy bodies (DLB). Clinical trials face difficulties due to the clinical and neuropathological heterogeneity of the condition with a diverse array of neuropathogenic mechanisms contributing to the clinical phenotype. The purpose of this review is to describe how recent advances in the development of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to alpha-Synuclein
Share to Alzheimer Disease

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Amyloid beta-Peptides

Share to Biomarkers

Share to Lewy Body Disease

Share to Patient Selection

Share to Phenotype

Share to tau Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 37387459
DOI: 10.1097/WCO.0000000000001173
PMCID: PMC10328538

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical trials in dementia with Lewy bodies: the evolving concept of co-pathologies, patient selection and biomarkers.PMID 37387459Read ↗

Clinical and pathological examples of Alzheimer's disease, dementia with Lewy bodies, and frontotemporal dementia.Semantic proximity Read ↗

Molecular Crossroads: Shared and Divergent Molecular Signatures in Alzheimer’s Disease and Dementia with Lewy BodiesSemantic proximity Read ↗

β-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies.Semantic proximity Read ↗

New horizons in the diagnosis and management of Alzheimer's Disease in older adults.Semantic proximity Read ↗

Disease‑Modifying Trials in Parkinson’s Disease: Challenges, Lessons, and Future DirectionsSemantic proximity Read ↗

Association between CSF alpha-synuclein seeding activity and genetic status in Parkinson’s disease and dementia with Lewy bodiesSemantic proximity Read ↗

Alzheimer’s disease copathology in dementia with Lewy bodies is associated with astroglial α-synucleinopathySemantic proximity Read ↗

α-Synuclein seed amplification assay detects Lewy body co-pathology in autosomal dominant Alzheimer's disease late in the disease course and dependent on Lewy pathology burden.Semantic proximity Read ↗

α-synuclein as an emerging pathophysiological biomarker of Alzheimer’s diseaseSemantic proximity Read ↗

LRRK2 -associated parkinsonism with and without in vivo evidence of alpha-synuclein aggregates: longitudinal clinical and biomarker characterizationSemantic proximity Read ↗

Invited Review – Understanding cause and effect in Alzheimer's pathophysiology: Implications for clinical trialsSemantic proximity Read ↗

LRRK2-Associated Parkinsonism With and Without<i>In Vivo</i>Evidence of Alpha-Synuclein AggregatesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.